TY - JOUR T1 - LATE-BREAKING ABSTRACT: Differences in <em>S. pneumoniae</em> serotypes distribution causing CAP in hospitalized adults in Spain according to comorbidities by a new urinary antigen detection (UAD) test. The CAPA study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA2581 VL - 46 IS - suppl 59 SP - PA2581 AU - Rosario Menéndez AU - Antoni Torres AU - Pedro Pablo España AU - Emilio Pérez-Trallero AU - José Luis López Hontangas AU - Francesc Marco AU - Ana Patricia Martínez de la Fuente AU - José María Marimón AU - Alexandra Gimeno AU - Catia Cilloniz AU - Ane Uranga AU - María Ercibengoa AU - César Balseiro AU - Cristina Méndez AU - Isabel Cifuentes Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA2581.abstract N2 - Background and objective: The presence of underlying conditions increases the risk of CAP. The 13-valent pneumococcal conjugate vaccine (PCV13) has demonstrated efficacy in the prevention of pneumococcal pneumonia and invasive pneumococcal disease in adults. In order to assess the burden of CAP, including non-bacteremic CAP, due to PCV13 serotypes (St), we explored differences in the distribution of PCV13 St in immunocompetent patients &gt;18 years hospitalized in 3 Spanish hospitals (November 2011-June 2014) by presence of underlying conditions.Methods: In subjects hospitalized with chest X-ray confirmed CAP, microbiological confirmation was sought by the novel UAD assay (Pfizer's PCV13 serotype specific urinary antigen detection test), BinaxNOW &amp; conventional cultures. Serotyping of pneumococcal isolates was accomplished in a central laboratory using Quellung reaction.Results: S. pneumoniae CAP was confirmed in 351 (29.8%) of 1179 included patients. Underlying conditions and/or risk habits were present in 87.4% of patients (mean age 67.7±17.9). Below table shows PCV13 St distribution in CAP by presence of specific underlying conditions according to UAD test results. Conclusion: Among at risk adults with chronic diseases, more than 50% of pneumococcal CAP cases were due to PCV13 serotypes. ER -